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Abstract: DNA mutations are the cause of many human diseases and they are the reason 
for natural differences among individuals by affecting the structure, function, interactions, 
and other properties of DNA and expressed proteins. The ability to predict whether a given 
mutation is disease-causing or harmless is of great importance for the early detection of 
patients with a high risk of developing a particular disease and would pave the way for 
personalized medicine and diagnostics. Here we review existing methods and techniques to 
study and predict the effects of DNA mutations from three different perspectives: in silico, 
in vitro and in vivo. It is emphasized that the problem is complicated and successful detection 
of a pathogenic mutation frequently requires a combination of several methods and a 
knowledge of the biological phenomena associated with the corresponding macromolecules. 
Keywords: single nucleotide polymorphism (SNP); pathogenic mutation; missense 
mutations; disease diagnostics; protein stability; protein interactions  
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1. Introduction 
There has been a rapid development of genome-wide techniques in the last decade along with 
significant lowering of the cost of gene sequencing, which generated rich and widely available 
genomic data. However, the interpretation of such genomic data as well as predicting the association of 
genetic differences with diseases still needs significant improvement. The problem stems from the fact 
that the effects of genetic differences on protein function vary widely making it difficult to decipher 
genotype-phenotype relationships. One plausible approach to reduce the ambiguity of disease 
association is to consider all molecular effects simultaneously by the means of combined efforts of  
in silico, in vitro and in vivo approaches. In this review, we summarize these computational and 
experimental methods that are used to reveal the potential impacts of genetic differences. The first 
section is devoted to the in silico methods and applications followed by a section on approaches and 
methods for in vitro investigations, and then a section reviewing the techniques and methods for  
in vivo studies. Finally, several methods described are applied to a case study to reveal the molecular 
mechanisms of several disease-causing mutations in two specific genes involved in X-linked mental 
retardations. These two genes, MECP2 (coding for methyl CpG binding protein 2 (MeCP2), which is 
important for the normal function of the cell) and the KDM5C (coding for lysine (K)-specific 
demethylase 5C, which participates in transcriptional repression of neuronal genes) were selected 
based on our ongoing research. 
2. In Silico Analysis of Pathogenic Mutations 
Genetic differences can cause a range of changes in the biophysical characteristics of macromolecules 
(DNA, RNA and proteins) including changes in stability, electrostatic properties, protein–protein, 
protein–DNA, protein–RNA and protein–membrane interactions, aggregation properties and structural 
characteristics. The latter includes changes in the H-bond network, pKa, hydrophobicity, flexibility 
and structural disorder. The potential impacts of mutations and methods used to study them are 
summarized in Figure 1. Understanding the rules that govern the changes caused by genetic mutations 
is crucial for disease diagnostics. Of particular interest are genetic differences resulting in amino acid changes 
of the corresponding protein, termed as non-synonymous single nucleotide polymorphism (nsSNP) or 
rare missense mutations. The methods developed to study the impact of single amino acid substitution 
cover a wide range of ideas from evolutionary and sequence-based predictions to detailed atomic 
energy-based methods, and several reviews albeit less comprehensive were published [1–8]. Here, we 
review these methods under broad categories and also provide examples of outcomes that advance our 
understanding of the changes in protein biophysical characteristics and interactions caused by mutations. 
2.1. Sequence and Evolutionary Analyses and Machine Learning Methods 
Disease-causing missense mutations are often found to occur at evolutionarily conserved positions 
that have a crucial role for protein structure and function. These sites are characterized through 
multiple sequence alignments, either with consensus sequences of the same protein in multiple 
organisms or with all homologues of the same protein. In many cases, the sequence identity implies 
structural similarity [9,10]. There have been a number of sequence-based methods developed to 
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identify whether a missense mutation is pathogenic or not [11–14]. Basically, the results from the 
alignment are normalized and then the degree of tolerance for specific mutations is produced based on 
sequence conservation data. The biggest advantage of these methods is that large databases of 
mutations can be screened efficiently. However, these methods are very sensitive to multiple sequence 
alignments, therefore, different predictions may be produced depending on the depth of the alignment. 
The list of web servers based on these principles include Sorting Intolerant from Tolerant (SIFT) [12], 
Alignment Grantham-Variation, Grantham-Deviation (Align-GVGD) [15], Mutation Assessor [16] and 
Multivariate Analysis of Protein Polymorphism (MAPP) [17]. 
Figure 1. Flowchart illustrating the methods (left) used for assessment of potential impacts 
(right) of DNA mutations on protein properties and interactions. nsSNP, non-synonymous 
Single Nucleotide Polymorphism. 
 
In addition, a number of methods combine evolutionary sequence conservation with other structural 
implications to characterize whether a mutation is pathogenic or not. These and other methods that 
incorporate different approaches concurrently are termed as combined methods. For example, 
PolyPhen-2 [18], makes the predictions based on sequence conservation, physico-chemical characteristics 
of the amino acids involved in the substitution along with the sequence environment of the mutation 
site and the structural features affected by the mutation. Other tools based on similar approaches 
include Mutation Taster [19], LS–SNP/PDB [20], SNPeffect [13], Predicting Protein Mutant Stability 
Change (MuStab) [21,22], MUpro [23], MutPred [24], SNPdbe [25], NetDiseaseSNP [26], HOPE [27] 
and SNPs3D [28]. 
In addition to, or in combination with evolutionary and sequence-based methods, several machine 
learning approaches such as Neural Networks, decision trees and Random Forests, Hidden Markov 
Models, Conditional Random Fields and Support Vector Machines (SVMs) have been used to predict 
the effects of single point mutations and specifically the stability changes upon mutations [29]. The key 
idea in machine learning is to direct the computer to learn how to solve a problem rather than 
providing the way to the solution. 
Neural network and SVM methods have widely been applied in nsSNP analyses. Although neural 
network based methods can achieve comparable performance to SVMs, the latter has been more 
popular recently possibly due to the availability of general high-quality implementation of SVMs [30]. 
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The I-Mutant [31] and I-Mutant2.0 [32] webservers use a neural network-based method and SVM, 
respectively, to predict the sign of free energy change upon mutations. When the free energy difference 
is obtained by subtracting the wild-type free energy from that of the mutant, the positive sign of the 
resulting free energy change indicates destabilization of the protein. I-Mutant, which uses structural 
information as well as temperature and pH to build the neurons, achieved an accuracy of 0.81 in 
predicting the sign of the free energy change upon mutations. I-Mutant was shown to outperform three 
other tools, namely the FoldX [33,34], Distance-Scaled, Finite Ideal Gas Reference (DFIRE) [35,36] 
and Prediction of Protein Mutant Stability Changes (PoPMuSiC) [37,38] servers, which use 
biophysics-based or statistical potentials. On the other hand, I-Mutant2.0 was trained to predict both 
the sign and the value of free energy change and it uses pH, temperature, neighboring residues and 
solvent accessibility in addition to mutation data. Although it achieves less accuracy compared to  
I-Mutant (0.62–0.80 depending on the input, whether sequence or structure-based are used, and the 
types of datasets), its ability to predict from protein sequences and not necessarily requiring structural 
information is the main advantage. 
The MuPro server [23] also use SVMs to predict the sign of free energy change or the value of free 
energy change from sequence or structure-based input. A local window centered on the mutated 
residue is used as an input, which enables a direct use of the sequence information to the SVM. 
Superior correlation (0.86) with the experimental data was obtained compared to I-Mutant [31] as well 
as FoldX (0.75), DFIRE (0.68) and PoPMuSiC (0.85). Another server named Machine Learning for 
Protein Stability Changes (MLSTA) [39] utilizing SVM together with evolutionary features and 
different integration techniques, in which both sequence and/or structure-based input can be used, 
achieved slightly higher accuracy (0.84–0.90) than the machine learning methods described so far.  
In a more recent study [40], the sequence-based data with evolutionary properties were combined 
together with predicted structural features to make predictions upon mutations. This method achieved a 
slightly higher correlation coefficient than the MLTSA obtained. A subsequent study [41], utilized the 
same approach with a modified dataset and in result, obtained slightly better accuracy than all the 
methods previously described. It is suggested that the previous studies might be overestimating the 
correlation between the calculated and experimental stability because of the nature of the databases 
that were used. Therefore, it was argued that a fair evaluation can only be achieved by excluding 
different mutations of the same protein and only including proteins that have low sequence similarity in 
the training datasets. Aside from that, this method included evolutionary and predicted structural 
features as well as physical amino acid parameters. As a result, 66% and 74% accuracy was achieved 
in determining the stabilizing and destabilizing mutations, respectively. Also, a correlation of 0.51  
was obtained in comparing the value of the change in free energy upon mutations. The results were 
found to be superior in comparison with modified versions of MuPro and I-Mutant2.0, i.e., predictive 
properties added accordingly, using the same dataset. 
In addition to the studies briefly reviewed above, there are a number of other studies and 
webservers available that utilize machine learning approaches to decipher the stability changes due to 
mutations. Namely, these servers are ESLPred [42], SVMProt [43], svmPRAT [44,45], Automute [46,47], 
FISH [48,49], onD-CRF [50], proSMS, PROTSRF, iPTREE-STAB [51], MuPro, SCide [52,53], 
SCpred [52], MuStab [21,22], PopMuSiC, PMut [54–56], SNAP [57], SNPs and Gene Ontology 
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(SNPs&GO) [58], Parepro [59], CanPredict [60], nsSNPAnalyzer [11,61,62], MutPred [24],  
Hansa [63,64], Mutation Taster [19] and BeAtMuSiC [65]. 
Besides studying the protein stability changes upon mutations, the sequence-based machine 
learning methods are also used for analysis of the effects of mutations on the subcellular localization of 
the corresponding proteins. It is anticipated that proteins function properly if they are in their native 
localization, although some exceptions do exist [66–68]. In about 1% of cases, nsSNPs occur at a 
signaling region that may cause protein subcellular delocalization [66–68]. The change in protein 
subcellular localization due to mutations often disrupts normal cell function by changing protein 
concentrations [66–68]. Therefore, these mutations are closely associated with phenotypes. Several 
computational tools are available to predict the protein subcellular localization as reviewed below. 
Most of the methods that predict protein subcellular location are sequence-based and utilize machine 
learning. The idea is to represent the proteins in a classifiable manner based on sequence and use a set 
of proteins with known subcellular locations to train the computer, and then the method can be used to 
predict subcellular locations of new sequences after the approach is tested with a control dataset. 
The protein subcellular location predictors mainly differ in several aspects including (1) the coverage 
scope, i.e., how many subcellular locations are covered; (2) multiple or single-site cases, i.e., whether 
proteins with multiple subcellular locations are predicted or not; (3) training dataset construction,  
i.e., the amount of sequence identity is tolerated in the database; (4) organism-specific approach,  
i.e., whether the approach is for multiple organisms or organism-specific; (5) representation of the 
protein sequence; and (6) prediction algorithms such as classifiers used in machine learning and testing 
algorithms [67]. In general, the desirable features are the wide coverage, inclusion of multiple sites, 
reduced sequence identity in datasets to exclude the homologous effects, rigorous protein representation 
method and organism-specific approach to increase the accuracy of the application along with solid 
learning and testing algorithms. 
Since the earliest subcellular predictors PSORT [69], SignalP [70,71] and TargetP [72], there has 
been substantial progress in the development of these predictors. One of these, Hum-mPLoc 2.0 [73–75], 
which is a human subcellular localization predictor, shows a substantial advancement over earlier 
versions, the Hum-Ploc and Hum-mPLoc. Briefly, the datasets included only proteins with 25% or less 
pairwise sequence identity, 14 localization classes were covered, and both single and multiple-site 
proteins can be predicted. Their method hybridizes a higher level GO approach [76] and an advanced 
pseudo amino acid composition method [75,77]. The accuracy reached is 63%. This method has 
recently been improved [78] and the server Gene Ontology Annotation SVM (GOASVM), which 
achieved 72% prediction accuracy, was made available. 
In another tool, LocTree2 [79], cellular protein sorting mechanisms are mimicked by utilizing SVM 
with a decision-tree like architecture of localization classes. A similar approach was also used in 
LocTree [80]. Eighteen localization classes are covered for eukaryotic proteins in LocTree2 as 
opposed to six in LocTree. Also, the sequence bias was reduced compared to LocTree by using the 
UniqueProt approach [81]. This corresponds to a threshold of 20% and 25% sequence identity  
for sequences longer than 250 amino acids for the development and testing datasets, respectively.  
The highest accuracy reached is 65% (eukaryotic proteins), showing comparable performance to the 
Subcellular Localization Predictor (CELLO v. 2.5) [82,83] and Wolf PSORT [84] for 52 eukaryotic 
proteins and 201 human proteins; the accuracy is 40% for the latter. 
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Recently, a Naïve Bayesian Classification (NBC) method was used utilized in n-gram-based 
Bayesian Localization Predictor (ngLOC) tool [85], which uses only the sequence information and is 
capable of predicting 11 sites for eukaryotic sequences with a high accuracy rate (89% for animal and 
91% for plant proteins). Its performance was compared to SherLoc2 [86] (predicts 11 sites, requires 
sequence and text-based input together with phylogenetic profiles and Gene Ontology (GO) terms) and 
WegoLoc [87] (predicts 10 sites, uses sequence and weighted GO input). The ngLOC was found to 
outperform SherLoc while showing a comparable performance compared to WegoLoc. Since ngLOC 
only needs sequence information as input, it is applicable to a broad genomic data. However, it was 
noted that the performance of the method strongly depends on the size and the similarity in the datasets 
used [85]. Other predictors include pTARGET [88–90] and YLock [91,92]. A more comprehensive list 
of similar webservers and other methods without webservers are listed in the PSORT website 
(http://www.psort.org). Here, we focused on predictors for eukaryotic proteins and refer the reader to 
other reviews for other organisms and also for more information [66]. In addition, it is worth 
mentioning a recently released database named COMPARTMENTS [93], which is a unified, 
comprehensive database of protein subcellular location with all protein identifiers and GO terms. 
Another area where the machine learning approaches are widely used is the prediction of folding 
rate changes caused by mutations. In one of these studies, the PRORATE webserver [94], a structure-based 
method using machine leaning is implemented to predict the folding rate changes upon mutations.  
In this approach, structural topology parameters with the complex network properties are used as the 
input features for support vector regression, which are then used to calculated the folding rates [94]. 
The method was shown to reach a correlation coefficient of 0.90 with respect to experimental folding 
rates. Other servers for calculating protein folding rates include K-Fold [95], FOLD-RATE [96–98], 
Prediction of long-range Contacts (PROFcon) [99] and Protein Property Prediction and Testing 
Database (PPT-DB) [100]. 
Similarly, machine learning methods can also be used to predict protein aggregation properties.  
For example, the Protein Aggregation Prediction Server—Random Forest (ProA-RF) and ProA-SVM 
servers [101] utilize a machine learning-based method. Out of 560 physico-chemical properties,  
16 were identified as important to protein aggregation, which then were used to make new predictions. 
These 16 features include hydrophilicity of polar amino acid side chains, various descriptions of 
hydrophobicity, accessibility reduction ratio, shape and surface features of globular proteins among 
others. The ProA was shown to outperform several other sequence-based predictors, namely, Waltz [102], 
PAGE [59], FoldAmyloid [103] and ZYGGREGATOR [104]. 
Considering the growth of data size in genomics, machine learning stands out as a substantially 
efficient approach. Besides efficiency, machine learning methods have an advantage over biophysics-based 
approaches due to their ability to learn complex nonlinear functions from mutation information to 
sequence and structure. However, they cannot predict the molecular mechanism of the effect and will fail 
in predicting mutations that are not observed in the training database. Because of that, biophysics-based 
approaches are very much needed. 
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2.2. Statistical Potentials 
The statistical potential energy functions are an alternative to the energy functions delivered from 
first principles, i.e., biophysics-based energy functions. Any structural characteristic in the 3D network 
of interactions in folded structures can be incorporated in the derivation, where these characteristics  
are converted to the corresponding free energies (potential of mean force) through Boltzmann  
statistics [105–107]. Despite their simplicity, these knowledge-based potentials have been used  
with considerable success in mutation-induced stability change predictions and many other 
applications [65,108–111]. Over time, the features that incorporate multi-body effects and collectivity 
have been added to increase the accuracy of predictions [108,112–115]. Although this can be 
considered an advantage over pairwise first principle-based potentials, statistical potentials are 
inheritably approximate because the statistics are collected from unrelated proteins, which implies that 
different structures used all belong to the same thermodynamics ensemble [116]. These approximations 
may result in a database-dependence in the delivered potentials [117]. Different statistical potentials 
such as distance-dependent potentials, distance-independent contact energies, backbone torsional 
potential and solvent accessible potential differ in how the statistics are calculated. Also, depending on 
the level of details included, there are coarse-grained residue level and atomic level potentials [116]. 
Among the most popular statistical potentials is the DFIRE [35], which is a distance-dependent, 
pairwise statistical potential. The DFIRE has been developed in search of a transferable, pairwise 
potential that is built on a physical basis with few or no adjustable parameters. Its database dependence, 
ability to capture 20 amino acid characteristics, solvent exposure dependence, transferability and 
accuracy in different applications were tested. It produced superior results in comparison with two 
other statistical potentials RAPDF [118] and KBP [109]. In addition, it was found to achieve a success 
rate of 70% compared to RosettaDesign [119] and FoldX [33,34]. Its poor performance in a few  
cases [35] can be attributed to the fact that it is a pairwise potential that only depends on distance,  
and also the solvent effects, polar–polar interactions and hydrogen-bonding are taken onto account 
only implicitly. Subsequent improvements include the development of DFIRE2 [36] and dDFIRE [35], 
which are based on orientation dependent interactions by treating each polar atom as a dipole with a 
direction. The dDFIRE and DFIRE2 servers produce a protein conformational free energy score based 
on provided structures. 
In parallel with the DFIRE development, another statistical potential, the Site Directed Mutator 
(SDM) [110] server, was developed to predict the stability changes due to nsSNPs. In the first test 
case, using the same set of input proteins as PoPMuSiC2, the SDM performed comparably, but not 
better than a number of other methods used in comparison when predicting whether a given mutation 
is stabilizing or destabilizing [110]. Other servers based on statistical potentials include Cologne 
University Protein Stability Analysis Tool (CUPSAT) [111] PopMusic2.0 [38], AUTOMUTE [46], 
BeAtMuSiC [65], MuPro[23], MuX-S [120], MuX-48 [23] and Hunter [1,121,122]. 
Aside from the statistical potentials, graph methods can also be used for screening large datasets.  
A recent study [123] used a graph-based method (mCSM server) in which distance patterns between 
atoms were used to represent the structural information of residues and to train the predictive models. 
mCSM was shown to perform significantly better than PoPMuSiC (1.0 and 2.0) [38], Automute [46], 
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CUPSAT [111], Dmutant [113], ERIS [124], I-Mutant2.0 [32] and SDM [110]. Another graph-based 
server is the Bonds on Graphs (BONGO) server [125]. 
2.3. Biophysics-Based Methods 
The statistical/knowledge-based potentials that were reviewed in the previous section can be 
replaced by physics-based empirical potentials (energy components). In this approach, typically,  
a linear interaction energy based formulation [126] has been used to calculate the binding free energy 
or folding free energy differences between the mutants and the wild type. A typical form of the free 
energy change as commonly used recently is as follows [127–130]: 
G = αሺ∆VvdWሻ + βሺ∆Velecሻ + γሺ∆SAሻ + δ (1)
In this formulation, the contributions of van der Waals energies, electrostatic energy (Coulombic 
and polar solvation energy) and nonpolar component of solvation energy (a term based on solvent 
accessible area) are calculated based on wild-type and mutant structures. Note that the general formula 
should include internal energy, an estimation of entropy and other energy terms, but various 
investigations have omitted them based on some assumptions or how they affect the overall 
performance of the method [127–130]. 
The parameters in the linear interaction energy (LIE) equation are optimized by fitting the predicted 
energy changes against large databases of experimentally determined charges of folding or binding 
free energies upon mutations. The free energy is calculated using the thermodynamic cycle shown 
below. Therefore, the overall free energy change is calculated in a path-independent manner (Figure 2). 
Figure 2. Schematic diagram of different states involved in the energy calculations and the 
corresponding equations used to predict the change of the folding free energy upon mutation. 
WT, Wild-type; MT, Mutant; Green: Folded WT protein in vacuum (V, gray); Light Green: 
Folded WT protein in solvent (S, blue); Violet: Folded MT protein in vacuum; Light Violet: 
Folded MT protein in solvent, Unfolded (U) states are represented by black curved lines. 
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Previous studies that used this approach differ in three aspects; how the initial structures for the 
wild-type and mutants are generated, which contributions to the free energy are taken into account and 
how the unfolded state is modeled. In one of these studies [128], an ensemble of initial configurations 
generated by the program Concoord [131] were used as initial structures. Also, the polar and nonpolar 
contributions to solvation energy were calculated through an efficient continuum solvent approach by 
solving the Poisson-Boltzmann equation using the DelPhi package [132] which then was averaged 
over the structural ensembles. Also, the entropy was calculated based on a quasiharmonic approximation 
proposed by Schlitter [133]. The final free energy equation included the electrostatic, van der Waals, 
solvent accessible surface area, and entropy terms with three adjustable parameters and a constant. 
This method named Concoord/Poisson-Boltzmann surface area (CC/PBSA server) produced a correlation 
coefficient of 0.75 for seven proteins and 582 mutants, which was compared to results from FoldX  
(R = 0.73, with five adjustable parameters) and Eris (R = 0.75, with 20 adjustable parameters) [128]. 
More recently, a similar approach [129] also used three adjustable parameters a constant, and in result, 
obtained a correlation coefficient of 0.72 for 10 proteins and 822 mutations. Energy minimized 
structures for wild-type proteins were used and the mutant structures obtained based on these wild-type 
structures only differed at the mutation site. The mutant residue side chain structure was modeled 
through a rotamer search. The unfolded state was represented using a 5-residue segment (mutant 
residue and two neighboring residues on each side) from the folded structures. 
Another recent study [134] used the method named scaled molecular mechanics generalized  
Born method (sMMGB) to calculate folding free energy differences for 1109 mutants (662 of them 
were used to fit the weights of each contribution to the energy). The free energies were calculated 
through the GB method in TINKER software [135] using three different molecular mechanics force 
fields and then averaged. The resulting free energies were scaled with a linear coefficient and a 
constant using the experimental free energy values of 662 mutants. The results were found to be 
comparable to those from Eris, FoldX and I-Mutant. In addition, the unfolded state was modeled with 
3, 5, 7, 9, 11 and 13 residue segments with the mutant residue in the middle and not surprisingly the 
smallest one provided best results. This is because of the fact that this approach assumes the same 
unfolded state for the rest of the protein except the segments considered and this assumption is 
expected to hold better with smaller length segments. 
Most recently, a similar physics-based linear interaction energy approach named modified MM-PBSA 
(molecular mechanics Poisson–Boltzmann Solvent Area) [130] was used to predict the protein stability 
changes upon mutations using large datasets (several thousand mutations). The binding free energy 
was composed of van der Waals energy, polar component of solvation energy and the solvent 
accessible surface area in the binding interface. Effects of using different minimization schemes and 
using different dielectric constants for solvation energy component were also assessed. The predicted 
energies produced the highest correlation constant of 0.69. This method provides fast predictions that 
are applicable to large datasets. 
Other resources that also use similar physics-based energy approach to calculate the stability 
changes upon mutations are the methods and webservers; Eris [124], FOLDEF [136], EGAD [137]  
and FoldX [33,34]. 
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In principle, the statistical mechanics based methods such as molecular dynamics (MD) give the 
most detailed information about the biological systems studied. The all-atom MD simulations produce 
the physical movements of the atoms in a system by numerically solving Newton’s equations of 
motion. As a result, a number of different properties can be obtained from the ensemble of structures 
generated by MD such as H-bond network, flexibility of the protein (based on fluctuations), and radius 
of gyration. In a recent MD study [138], the observed conformational changes in the mutant F28L 
compared to the wild-type structure of RAC1 protein in a ~300 ns long MD simulation. It was shown 
through the RMSD, RMSF and H-bond network change that the mutation caused loss of native 
conformation in the Switch I region, which is associated with its oncogenic transformation. 
Although detailed structural and dynamical information about the proteins can be obtained through 
the MD simulations, the direct calculation of free energy from the standard MD is possible through 
more advanced methods. In principle, the most accurate methods to calculate free energy differences 
include free energy perturbation (FEP) and thermodynamic integration (TI), which use the trajectories 
from MD or Monte Carlo (MC) simulations [139–142]. First, a real or alchemical pathway is defined 
from one state to another. Then, in the TI approach, the free energy change between the two states is 
calculated by integrating over enthalpy changes along the path. On the other hand, in the framework of 
the FEP approach, the free energy difference from state A to B is obtained using Boltzmann sampling 
through the equation; ∆G = −kBTln (e−(EB−EA)/kBT), where kB is the Boltzmann constant and T is temperature. 
Although, the coupling of these methods with several advanced sampling approaches increases the 
efficiency of these methods, they still are not suitable to study large datasets of mutants. Therefore, 
more efficient methods, as summarized in this section, based on approximations to the free energy have 
been developed to predict the protein stability changes that are applicable to large databases of mutants. 
In addition for studying the free energy changes, the biophysics-based methods were used to study 
the protein kinetics such as protein association/dissociation rates, protein folding rates and aggregation 
rates. Apart from being exhaustive, we will briefly review representative studies in each of these aspects, 
starting with the TransComp server [143], which is based on the transient-complex theory [144] for 
predictions of protein–protein and protein-RNA association rate constants. In this approach, a two-step 
reaction mechanism is assumed as shown below (Equation (2)), in which the transient-complex, A*B,  
is first formed and then the functional dimer. The two proteins have a near-native separation and right 
orientation at the transient-complex but yet to form specific short-range interactions of the native complex. 
 
(2)
where, the overall rate constant is ka = kDkc/(k−D + kc). At this point, the method assumes that the 
association is diffusion limited as opposed to conformational rearrangement (kD >> kc and also kc >> k−D), 
therefore once the transient-complex is formed, the reaction proceeds to form the native complex.  
The rate constant for the formation of the transient-complex by random diffusion is called the basal 
rate constant, ka0 and the overall association rate constant is calculated by ka = ka0e−∆Gel*/kBT where 
∆Gel* is the electrostatic interaction free energy of the transient-complex. The diffusion is efficiently 
modeled through Brownian dynamics, and the electrostatic free energy is calculated through the  
Poisson–Boltzmann equation. Again, this method works for diffusion limited cases that correspond to 
cases where the association rate constant ≥~104 M−1·s−1 (the full range of association rate constants 
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span a range of 1–1010 M−1·s−1). Single point mutations are not expected to make a significant change 
in terms of the random diffusion because the proteins are treated as rigid bodies with no charge for 
efficiency during this process, therefore, the accuracy of the change in rate constants of mutants with 
respect to wild-type structures strongly depends on the electrostatic free energy calculation. 
Other approaches have also emerged from the need for a fast and widely applicable method.  
In general, methods like standard MD or biased MD are either limited by time and/or the complexity 
of the procedures. A structure-based method was developed [145] to predict both dissociation and 
association constants along with equilibrium rate constants. The structural features were determined 
based on a diverse dataset of 62 protein complexes with known experimental rate constants. This method 
uses structural information as only input and linear models were developed for predictions based on 
the structural input using Bayesian information criteria [146]. In result, the method produced 
correlation constants of 0.80, 0.73 and 0.77 for koff, kon and kD, respectively. 
Recently, a method [147] based on hotspots data was developed to predict the change in protein–protein 
dissociation rates upon interface mutations. In general, hotspots are defined as a set of interface 
residues that destabilize the protein changing the binding free energy by 2 kcal/mol or more upon 
being mutated to alanine [148]. In this approach, a set of descriptors are generated through machine 
learning using the data from alanine scans of hotspots and hot regions in relation to changes in 
dissociation rates upon mutation. As a result, a mutation to any residue type can be studied as well as 
multi-point mutations with an accuracy of 0.79 compared to experimental off-rates. 
Single point mutations also affect protein/peptide aggregation kinetics depending on their effects on 
the protein biophysical characteristics. In a simple approach [149], the changes in hydrophobicity 
(∆Ihydr), secondary structure propensity (∆ISS), and charge (∆Ich) were related to the ratio of wild-type 
and mutant protein/peptide aggregation rates (log (vwt/vmt)) with coefficients obtained by fitting to 
experimental values as shown below (Equation (3)) with three adjustable parameters αhydr, αSS, αch: 
log ൬vwtvmt൰ 	= αhydr∆I
hydr + αSS∆ISS + αch∆Ich (3)
Despite its simplicity, this type of consideration produced a correlation coefficient of 0.8 with 
experimental and predicted aggregation rates for a series of proteins and peptides. 
Another simple approach [150] that utilized a simple mathematical expression with no adjustable 
parameters produced a correlation coefficient of 0.85. The method is based on amino acid properties at 
the mutation site, total charge and β-propensities as shown below (Equation (4)): 
vmt
vwt
= ΦhΦβΦAΦC (4)
where, Φh is the ratio of solvent accessible surface area of mutant residue to wild-type residue or  
vice versa depending on whether the mutation is from apolar to apolar, i.e., no dipole or charge in side 
chain or polar to polar. If the mutation is from polar to apolar or vice versa, then dipoles are used.  
The second factor (Φβ) is the β-propensity of mutant to wild-type. The last term, ΦAΦC, approximates 
the effect of aromatic residues (A) and total charge (C); ΦAΦC = e(ΔA−Δ|C|/2). 
Another method, the TANGO server [151–153], used a statistical mechanics algorithm based on the 
physico-chemical characteristics of secondary structure formation with the assumption that the core 
regions of aggregates are fully buried. The TANGO algorithm basically calculates the partition 
Int. J. Mol. Sci. 2014, 15 9681 
 
function of the phase space, where every segment of each peptide is allowed to populate different 
conformational states according to Boltzmann distribution to form aggregates. The energetic penalty 
for complete desolvation of the core regions in aggregates involves contributions from solvation,  
van der Waals, H-bonding, entropy and electrostatics. As a result, solvation propensities of 179 peptides 
were correctly predicted with a correlation coefficient of 0.74. 
Moreover, a method, named Prediction of Amyloid Structure Aggregation (PASTA) [154,155] was 
developed to calculate sequence-specific interaction energies between pairs of protein fragments using 
statistical analyses of the native folds of globular proteins. In parallel to PASTA, the AGGRESCAN [156] 
webserver was developed, which calculates the aggregation propensities based on the predetermined 
aggregation propensities through experimental data of each amino acid in given sequences. 
3. In Vitro Analysis of Pathogenic Mutations 
SNPs encompass a high density distribution of genetic variation in the human genome. Each SNP 
represents a difference in a single nucleotide, including transition, transversion, insertion or deletion 
between individuals of a biological species or alleles in the paired chromosomes. Since 1994 SNPs 
have been proposed as the third generation of genetic markers, as well known as the restriction fragment 
length polymorphism (RFLP) and simple sequence repeats (SSRs) [157,158]. Over 10 million SNPs 
have been found at a frequency of 1–10 in 1000 base pairs through the whole human genome, which 
may affect individual development and reflect human evolution. Immediately following their discovery, 
SNPs attracted the attention of more and more researchers. SNPs contributed to the susceptibility for 
complex diseases based on the statistical genetics [159], and make whole-genome association studies 
more feasible, e.g., Alzheimer’s Disease, Breast Cancer and Coronary Heart Disease [160]. In this 
section, we will review the most common and newly developed detection methods and functional 
screening for SNPs. 
3.1. Single Nucleotide Polymorphisms (SNPs)—Detection Methods and Technology 
During the past decade, new detection methods and technologies with high sensitivity were 
introduced to help detect SNPs more efficiently, such as Next Generation Sequencing (NGS), 
restriction fragment length polymorphism, and random amplified polymorphic DNA. At the same 
time, a prototype of the SNP database was established that compiled the contributions from many 
different research groups. However, most of the traditional technologies were based on the detection  
of gel electrophoresis, which are difficult to perform in high-throughput and multiplex format. The 
development of SNP microarray technology makes SNP detection highly efficient, fully automated, 
and relatively inexpensive. It is even possible to apply SNPs as aids for molecular diagnostic, clinical 
examination, drug design and individual medical diagnosis. To collect and catalog the molecular 
variation within SNPs, researchers also submit their data to a SNP database, an online resource that  
is designed to contain all identified genetic variation. By accessing the database, researchers are not 
only promised to advance the variety of genetically based natural phenomenon, but also investigate 
evolutionary relationships. However, no single method meets the needs of all studies. In the next 
section we will discuss major methods and technologies that are widely used. 
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3.1.1. Traditional Methods for SNP Genotyping 
To scan for new polymorphisms and identify known gene variants in target genome, researchers 
have developed a number of technologies driven by the Human Genome Project. By referencing 
against the completed human genome sequence, DNA sequencing to the target genome is the most 
direct and accurate method. It is used as the gold standard for SNP genotyping. Like others, the DNA 
sequencing technologies are evolved from a single but complicated method to a variety of automated 
methods to meet different requirements. The development of next-generation sequencing technologies 
promoted whole genome SNPs screening at levels not previously possible [161,162]. As it has become 
more widely accessible, usage has extended from basic research into clinical contexts. The challenge is 
not genome sample preparation or the cost, but how to analyze the newly generated data and how to 
handle the rising error rate. The NGS technologies lead sequencing base call accuracy range from 
99.9% to 99.9999% [163]. Even for the lowest error rate, the absolute number of miscalled genome 
variants is still unwieldy. Indeed, post-processing techniques to help reduce the uncertainty in the final 
genotyping variant call including K-Spectrum approach, Suffix Tree/Array approach, Multiple Sequence 
Alignment approach and Hybrid approach have been developed [163]. Careful sample selection and 
preparation may save more time and cost for a given gene based on these two broad areas; known  
SNP identification and unknown SNP exploration. For both global and regional target genomes, DNA 
sequencing followed by various gene amplification approaches are suitable for detecting known and 
unknown SNPs, but more options are available when screening known SNPs in individual genomes, 
especially for disease patients. Two classical methods are discussed below. 
The first SNPs found in a global approach were restriction fragment length polymorphisms  
(RFLP) [164]. As described in Figure 3A, high quality genomic DNA from multiple individuals are 
digested with selected restriction enzymes, then the resulting fragments are separated by gel 
electrophoresis and transferred to nylon filters. A random genomic probe is used for identification of 
variation in the restriction fragment lengths. Only SNPs in the restriction site or in the probe sequence 
can be detected. The introduction of Restriction Fragment Length Polymorphism Analysis of  
PCR-Amplified Fragments, in which the primer was designed with an additional mismatch base 
adjacent to the SNP site did not, unfortunately, improve detection [165]. However, RFLP is a  
simple and low-cost method to detect known SNPs. For example, a T to A transversion in the middle 
position of codon 6 of hemoglobin causes sickle-cell disease. This mutation generates the sequence  
5'-CTGAGG-3' that is recognized and is cut by DdeI [166], and a short fragment can be detected in the 
patient genome. 
Random amplified polymorphic DNA (RAPD) is the first PCR based molecular marker technique 
developed [167] and then applied to SNP detection for various organisms [168,169]. Random and 
variable sequences of genome PCR products are generated by random primer sets and produce a 
pattern of bands resulting from electrophoresis. Presence/absence of certain size product fragments 
indicates individual variety (Figure 3B). Mismatches between the primer and the template resulting in 
the absence, or decreased transcripts of specific bands, indicates the position of a SNP. By designing 
longer specific primers, the product DNA can be sequenced to identify the gene variants. 
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Figure 3. Principles of Restriction Fragment Length Polymorphisms (A) and Random 
amplified polymorphic DNA (B). The resulting fragments from target genome DNA are 
generated (left) and separated by gel electrophoresis followed by appropriate detection 
approach (right). To perform restriction fragment length polymorphisms (RFLP), genome 
DNA from variant individuals are subject to restriction digest (restriction sites are indicated 
by triangle) and random genomic probe (complement sequences are indicated by empty 
rectangle) is used for Southern Blot detection. Bands shown in Southern Blot represent  
(1) wild type; (2) loss of restriction site; (3) gain restriction site; (4) deletion of DNA 
fragment; (5) insertion of DNA fragment, from top to bottom. To perform RAPD, random 
primer sets are used to amplify genome DNA. Each matched primer set (full line arrow) 
generates a specific size product that appears in both wild type (top) and mutant (bottom) 
genome. Meanwhile mismatched primer (dashed line arrow) causes band absent in mutant. 
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Needless to say, these classical methods are laborious and time consuming. High-throughput and 
multiplex analysis is required for whole genome SNP mapping and individual SNP detection.  
SNP microarray technology using a high-density oligonucleotide probe array makes it possible to 
perform whole genome SNPs genotyping. The microarray platform enables microsphere-based 
microarray [170], fiber-optic microarray [171] and glass substrate microarray [172]. The marker density 
among the various technologies ranges from hundreds to millions. In the Lettuce Affymetrix SNP 
Array, for example, 6.4 million markers, spread evenly across whole genome can be simultaneously 
analyzed [173]. Thus, the bottleneck for high-throughput SNPs detection is no longer the microarray 
platform, but the methods and technology of DNA preparation. 
3.1.2. High-Throughput Method for SNP Genotyping 
Allele-Specific Primer Extension (ASPE) is a solution based, sequence specific enzymatic reaction 
technology allowing the analysis of multiple SNPs in a one-step single reaction [174]. To determine 
the target genotype, a pair of allele-specific primers for each mutant or polymorphic site that differ at 
their 3' end, complementing to either of the variant alleles, are immobilized at their 5' end onto the 
array. Extension of the detection primers with labeled dNTPs is then performed in a template-dependent 
manner. To evaluate the result, an appropriate array scan is performed to quantify and compare 
between each primer pair by labeled probe. The signal ratios fall into distinct categories defining the 
genotype at each site. However, the caveat for this method is that microarray is not reusable and the 
extension reaction is technically challenging to perform on the microarray. For these reasons, a variety 
of changes to the original method have been made, one of which, a modified two-phase procedure, is 
described here [175]. Instead of 5' end immobilized on microarray, a capture sequence is used to 
recognize and capture the target onto the solid microsphere-based microarray. The capture phase is 
followed by the genotype determination phase. Taking advantage of this modification allows sequence 
labeled microsphere arrays to be used for new template detection. Most recently, the major 
histocompatibility complex (MHC) class I chain-related gene A (MICA) genotyping was developed by 
ASPE on microarrays [176]. By using 20 control primers, strict and reliable cut-off values were 
applied to select high-quality specific extension primers. Fifty-five allele-specific primers were 
selected as optimal primers, in which forty-four primers could be initially used. On the basis of showing 
the same results as those by nucleotide sequencing, ASPE on microarrays provide high-throughput and 
also high accuracy genotyping for MICA alleles used in population studies, disease-gene associations 
and hematopoietic stem cell transplantation, although overmuch primer designation is still required for 
gene specific optimization. 
Based on the principle of ASPE, a commercialized product called GoldenGate™ [149] allows up to 
106 multiplex for custom SNP microarray by using only 250 ng genomic DNA. For each SNP locus,  
a pair of allele-specific oligonucleotides and one locus-specific oligonucleotide is designed. All three 
oligonucleotides contain sequence complementary to genomic DNA and also universal PCR primer 
sets. The locus-specific oligonucleotide is designed complementary to the downstream sequence  
10–20 bp from the SNP site, to prevent repeat sequence as well as palindromic sequences and increase 
the specificity of the reaction. DNA polymerase is used to fill the gap between the two kinds of 
oligonucleotides. The resulting product is used as a template for amplification by universal PCR 
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primers with various fluorescent labels followed by hybridization and detection as described for ASPE. 
GoldenGateTM provides high throughput genotyping at the multiplex levels that fulfills the requirement 
of custom genotyping, and also the accuracy can achieve 96.64% [177,178]. In a study [179], 
GoldenGate™ offers substantial increases in accuracy for pooling compared to other commercial 
microarray technology, and this advantage greatly extends the usefulness of pooling, making the 
limitation of whole genome studies the available sample size, rather than cost. 
Single Base Extension (SBE) technology is a robust technology that allows for identification of a 
known SNP site and is commonly used for low-density array development and DNA preparation.  
It was invented by Philip Goelet, Michael R. Knapp and Stephen Anderson in 1999 to measure DNA 
methylation levels in the human genome [180]. The method is to design a dual functional DNA 
oligomeric primer in which the 3' end complements to the locus that is to be genotyped and the 5' end 
complements to a sequence tag. In the presence of DNA polymerase and labeled ddNTPs, the 3' end of 
the primer appends a single DNA base and undergoes amplification exponentially. The identity of this 
appended base indicates the genotype of the original template. Since each locus has a distinct tag,  
the genotyping reactions can be performed as highly multiplexed and separated by hybridization to the 
reverse complement sequence tags on the microarray. This method allows researchers to indicate SNPs 
by using universal DNA arrays such as all k-mer arrays, and provides a flexible, high-throughput and 
cost-effective alternative to genotyping assays [181]. Previously, over 100 SNPs were genotyped and 
over 5000 genotypes were obtained by using SBE microarray technology with only an approximate 
1% error rate [182]. Based on a similar principle, SNPstream ultra-high throughput technology was 
developed by using multiplexed PCR (up to 12-plex PCR sets) in conjunction with SBE genotyping 
technology. Single nucleotide appending is manufactured in a 384-well format on a glass-bottomed 
plate [183]. Because two different fluoresceins are labeled for each one PCR primer set, only one 
genotype can be detected in a single reaction, which limits the application of SNP stream in clinical 
practice, and this technology is not readily multiplexed for high-throughput applications. 
TagMan probe arrays are designed based on fluorescence resonance energy transfer (FRET) to 
quantify nucleic acids. It combines the advantages of real-time quantitative PCR and gene expression 
microarray methods, and reduces their limitations. A conventional TagMan probe is designed as a 
double-labeled fluorogenic probe, the donor fluorescent dye is attached to the 5' end and the acceptor 
fluorescent dye is attached to the 3' end. With 5' nuclease activity of DNA polymerase, the donor  
will be cleaved during the extension step of the PCR, which reflects single nucleotide un-pairing by 
evaluation of FRET efficiency. The modified TagMan probe consists of an amino group at the 3' end 
for immobilization, poly(T)20 as a linker arm with a reporter (donor) fluorescent dye, and a dabcyl 
group at 5' end as the quencher (acceptor). The modified TagMan probe is immobilized onto a glass-based 
microarray so that a real-time reporter signal restoration can be detected by cleavage of 5' end 
quencher during the PCR to represent the feasibility of real-time nucleic acid analysis in parallelism 
directly from genomic DNA [184]. Although TagMan probe arrays have advantages in specificity, 
sensitivity and dynamic changes of fluorescence intensity at various PCR cycle numbers for SNP 
analysis, the specificity is significantly impacted as multiplexing increases, because PCR amplification 
and TagMan probe cleavage are performed in a single reaction [185]. 
The Ligation-rolling Circle Amplification (L-RAC) is a flexible, non-gel-based SNP detection 
method. Circularization of padlock probes with T4 ligase or thermostable ligase is used to discriminate 
Int. J. Mol. Sci. 2014, 15 9686 
 
point mutations in target DNA sequences specifically and sensitively. A short padlock probe includes 
the sequences at both 3' and 5' ends, which are complementary to downstream and upstream sequences 
of target SNP in a single copy gene. The probe will be circularized by a high fidelity thermostable 
ligase, or else fail in ligation causing by a single base mismatch at the 3' end. The other element of the 
short padlock probe contains a tag sequence and restriction enzyme site. By rolling circle amplification 
and enzyme digestion, the resulting products can be used for hybridization analysis [186]. A scalable 
method [187] based on L-RCA was reported to analyze numerous target sequences in multiplexed 
assays. All 13 sets of padlock probes tested were co-amplified and identified by hybridization to 
standard tag oligonucleotide array for analysis SNP among patients with Wilson’s disease [187]. The 
key feature of L-RCA, unimolecular dual recognition probes, allows lower probe concentrations that 
reduce the risks of amplification artifacts. On the other hand, the design requirements of the probes also 
limit the applications in high-throughput genotyping analysis. 
Molecular Inversion Probe (MIP) is derived from L-RCA, in which the linear oligonucleotides were 
used as padlock probe sets providing sufficient specificity. An additional exonuclease treatment 
removes non-reacted linear probes, and thus avoids cross-talk at the detection step. The MIP is 
designed with seven functional components: two restriction endonuclease enzyme recognition sites 
(e.g., HindIII, BamHI, EcoRI, EcoRV and XbaI); two regions complementary to the target genomic 
DNA, downstream and upstream to the SNP site respectively, at each termini of the probe; two general 
PCR primers common to all probes and one universal tag sequence for each locus. To start the 
procedure, linear probe is circularized after matching to target genomic DNA via an appending base at 
the 3' end, which matches the SNP site. Successfully reacted probes are linearized, released from the 
genomic DNA and amplified using the primer set. The resulting product containing inversed sequence 
is captured with the tag sequence. The multiplexing level ranges from 102 to 106, based on the capture 
platform [188]. However, four parallel reactions are usually required for each SNP variant, and longer 
probes are required for large gaps, which increases the cost required to achieve the expected sensitivity 
and uniformity. 
Affymetrix SNP array technique became popular and is widely used for whole-genome scans of 
polymorphic genetic markers. An algorithm was designed and developed by Affymetrix for 
genotyping SNPs based on the intensities, and the derived genotypes are available for further analysis. 
Prior to the bioinformatics analysis, the whole genome is fractionated with selected restriction enzymes 
and the resulting fragment lengths range from 200 to 2000 bp, followed by ligation of adapters to 
fragments, and a subset of the genome is amplified by single primer amplification reaction and is ready 
for hybridization. Various arrangements and combinations of the restriction endonuclease enzymes 
allows for multiplexing ranging from 104 to 106. A modification on this method, based on using 
multiple arrays at the same time and a model that relates intensities of individual SNPs to each other, 
allows for annotating SNPs that have poor performance, thus extending the application of the 
Affymetrix SNP array [189]. Obviously, by the limiting restriction enzymes and sites, this method is 
incapable of custom application, as SNPs cannot be specified. On the other hand, the high-throughput 
whole-genome coverage compensates for the limitation. 
In summary, microarray technological advances help identify whole genome SNP data from 
multiple sources efficiently, especially for prokaryotes and other genomic sequences of low 
complexity. However, the efficiency and design of the amplification reaction are still limiting the 
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appliance of microarray, when faced with genomes as complex as human genomes. The SNP database 
offers a solution for the overwhelming multiplex of human genomic DNA. By accessing a current SNP 
database, like dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and JSNP (http://snp.ims.u-tokyo.ac.jp/), 
researchers are able to perform physical mapping, population genetics, investigations into evolutionary 
relationships, not to mention being able to quickly and easily search for variation in the gene of 
interest. These data now allow researchers to investigate the functional SNP involved in human diseases. 
3.2. Functional SNP Screening 
As the studies based on SNPs advanced, researchers began to notice the increasing probability of 
false-positive results generated by traditional statistical methods. To solve this problem, a fusion of 
traditional and newly developed in vitro methods and techniques were introduced to identify functional 
SNPs from overwhelming candidate loci. Here, we will go over the most important methods and 
technological development as listed in Table 1. Then, we follow the historic timeline of an X-linked 
gene and explain methods that contribute to each research milestone (Table 2) and also provide an 
outlook for future directions. 
Table 1. Important methods and technological developments for understanding various 
single nucleotide polymorphism (SNP) loci. 
SNP Loci Subject of Investigation Methods 
Non-coding 
region 
Gene transcription Chromatin immunoprecipitation;  
Electrophoretic Mobility Shift Assay;  
Dual-luciferase assay; Real Time PCR 
mRNA degradation 
Gene translation 
Gene expression 
Immunoblotting; Enzyme-Linked Immunosorbent Assay; 
Immunofluorescence 
Coding region 
Protein structure Crystallization; Nuclear Magnetic Resonance 
Conformation Stability Circular Dichroism Spectroscopy; Intrinsic Fluorescence 
Kinetics Binding assays; Enzyme assays 
Most commonly, SNPs are found in the non-coding regions, or as synonymous SNPs in coding 
regions that do not alter the amino acid sequence of the expressed protein. In both cases, SNPs are 
invisible to the resulting phenotype and play a role only as a genetic marker. SNPs can have effects 
based on their distribution within the elements of the gene, which includes regulatory regions, five prime 
untranslated regions (5' UTRs), introns and exons and three prime untranslated regions (3' UTRs).  
To identify functional SNPs, various methods are applied to specific coding regions. In general,  
the regulatory region is made up of a promoter, an enhancer and other structural domains. The main 
functions of these regions are to control the transcription rate by binding of transcription factors, or 
bringing in a loop-like structure to enhance the transcription factor binding efficiency or repress the 
transcription as needed. SNPs located in this region may change binding affinity between the 
transcription factors and the DNA of the gene. Either strengthening or weakening binding affinity, or 
upregulating or downregulating mRNA transcription can regulate the level of protein expression.  
The 5' UTR, also known as the leader sequence, is directly upstream of the start codon in the mRNA 
and plays an important regulatory role in the translation of a transcript in different ways [190]. The SNPs 
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in this region will in many cases impair the translation process. It is reported [191–193] that microRNAs 
(miRNA) interacting with the 3' UTR of mRNAs also play a role in regulating gene expression. For 
example, a SNP localized in the pri-miRNA or 3' UTR can regulate degradation of mRNA, so it can 
regulate the expression of the gene [193]. Although differing in mechanisms, SNPs localized in 
regulatory region, 5' UTR and 3' UTR, have same effect on the level of the gene expression. Therefore 
similar research methods are used to understand the SNP in that region for a specific gene. 
Table 2. Methods used in MECP2 studies along with the historic timeline of research milestones. 
Year Results Methods Reference 
1992 
MECP2 was firstly identified in human  
X chromosome. MeCP2 belongs to MBD protein 
family, and binds to methylated DNA 
Immunofluorescence;  
Southwestern Assay 
[194] 
1997 MeCP2 acts as a global transcriptional repressor 
In vitro Transcription Assay; 
Western Blot 
[195] 
1999 
Four mutations of MECP2 gene causing Rett 
syndrome were identified 
Conformation-sensitive gel 
electrophoresis; DNA sequencing 
[196] 
2000 
Missense mutations in MBD domain lost 5mC 
binding specific. Interruption of TRD domain lost 
repression to various genes 
Southwestern assay;  
In vitro Transcription Assay 
[197] 
2003 
MeCP2 regulate BDNF gene by binding to  
promoter IV 
EMSA; ChIP; Real-time reverse 
transcription PCR 
[198] 
2003 
MeCP2 compact chromatin via its three  
AT-hook domain 
EMSA; Sedimentation Velocity; 
Electron Microscopy 
[199] 
2005 
MeCP2 bind to four-way junction DNA in a  
structure-specific methyl-CpG-independent manner 
Gel-retardation assays [200] 
2008 Mutational hotspots have effects on MeCP2 stability 
Fluorescence Spectroscopy; 
Circular Dichroism 
[201] 
2012 
MeCP2 bind specifically to 5-hydroxymethylytosine, 
enriched in the target gene promoter 
Substrate Affinity pull-Down; 
Methyl-DNA-IP Sequencing 
[202] 
2013 
Mutational hotspot R306C, proximal to the T308 
Phosphorylation site, abolishes the binding to the 
NCoR complex 
Phosphotryptic-mapping;  
Peptide binding assay; 
Immunofluorescence 
[203] 
2013 
MeCP2 compact chromatin via its three  
AT-hook domain 
Real-time reverse transcription 
PCR; Immunofluorescence 
[204] 
Binding affinity between regulatory factors and gene elements is usually investigated to understand 
regulation of the gene expression. Electrophoretic mobility shift assay (EMSA) is a common affinity 
electrophoresis technique to investigate DNA–protein or RNA–protein interactions. The rate of 
immigration reduction in the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
represents a protein or protein complex that is capable of binding a given DNA or RNA sequence, and 
stoichiometry between binding protein and DNA or RNA. It is widely used in determination and 
quantification of interaction between ribosomal transcription factors and promoter sequences with 
SNPs or in some cases between translation factors and 5' UTR. 
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To take into account epigenetic factors, chromatin immunoprecipitation (ChIP) was developed to 
reveal the binding protein within a specific genomic region or the associated genomic regions to a 
specific protein in the cell. After shearing the DNA or RNA into fragments, the protein-DNA or 
protein-RNA complexes are isolated and concentrated by using appropriate antibodies or complementary 
nucleotide sequences from cellular lysates. In vivo, gene activation or inactivation is regulated by 
epigenetic mechanisms, such as genomic DNA methylation, histone modification and post-translational 
modification of transcription factors. As a cell-base assay, ChIP retains the epigenetic status of the 
native state within a cell. Sequencing or mass spectrometry is used to analyze purified products. 
Complementing the more specific EMSA, ChIP is applied to whole genome analysis by  
combination with microarray technology or NGS, and provides an option to perform high-throughput 
or de novo analysis. 
The Dual-luciferase Reporter Assay System (DLR) [205] is used to measure two luciferase 
activities, Renilla and firefly luciferase, in a single protein extract. It is a robust, simple, reproducible 
and highly sensitive method for examining gene expression in bacterial, yeast [206] and mammalian 
cells [205]. The gene encoding firefly luciferase is fused to the test promoter and integrated into the 
genome to be examined. Meanwhile the Renilla luciferase is used as a control for normalizing the 
assay by fusing to a constitutive promoter and also integrated into genome. The ratio of the luciferase 
activities represents the level of gene expression. Since both luciferase activities have a linear range 
covering at least five orders of magnitude, the use of DLR for rapid examination and quantification of 
gene expression has gained increased popularity. The only limitation for DLR is the appropriate 
vectors containing the luciferase reporters for different systems. However, with more organisms being 
adapted for the DLR assay, researchers have recently constructed a 3' UTR and specific miRNA 
fragment downstream of the luciferase gene to study functional SNPs located in 3' UTR [207]. 
Humans are a sexually dimorphic species. To ensure equivalent gene expression levels from the  
X-chromosome, dosage is compensated by X-chromosome inactivation [208]. For autosomes,  
the epigenetic phenomenon such as the expression of a certain gene is inherited in a parent-of-origin 
specific manner is called gene imprinting [209]. Based on allele variant expression in heterozygotes, 
researchers are able to examine the effect of a single SNP on gene expression [210]. The commonly 
used methods have been discussed in traditional SNP detection methods above.  
In vitro functional studies of the genes having nsSNPs are important to gain better understanding of 
the molecular mechanism involved in normal and mutant gene function. Most in vitro protein studies 
are started from isolated proteins from a number of sources, for example expression abundant tissue,  
in vitro expression or recombinant expression, followed by an examination of the protein carrying out 
its functions in a controlled environment. Here we focus on specific applications for the study of 
nsSNPs. Three major profiles of certain proteins are considered and investigated by in vitro methods; 
they are gene expression, protein structure and enzyme kinetics. 
Protein immunization is the most commonly used technology to detect the loci, expression level, 
truncation and post-translational modification of proteins of interest. Immune responses can be elicited 
against full-length proteins or synthesized peptides with either the wild-type sequence or containing  
a nsSNP. The specific binding between an antigen and antibody give an exclusive antibody-antigen 
complex. By conjugating fluorescent, luminescent, radioactive or enzymatic labels, researchers are 
able to evaluate immune reaction in different ways. For example, immunofluorescence, immunoblotting 
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and enzyme-linked immunosorbent assays are generally used. Since a monoclonal antibody is made 
from identical immune cells derived from one unique parent cell, in contrast to polyclonal antibodies, 
it has the monovalent affinity to recognize even a single amino acid mutation [211]. Compared to the 
other methods mentioned above, immunoassays provide a visualization method able to specify the 
size, locus and expression level of target proteins. 
Protein structure and conformational studies are used for determining the secondary to quaternary 
protein structures and even protein-substrate complexes. X-ray crystallography can obtain the mean 
positions of atoms in a crystal from electron density, which gives the most abundant information for 
protein structure followed by computational analysis. However, a protein placed in a non-physiological 
environment can occasionally lead to aberrant conformational changes. Also, nsSNPs may change the 
structure of the protein and the mutant may fail to crystallize. To circumvent these problems, researchers 
have used nuclear magnetic resonance spectroscopy (NMR) [212] or circular dichroism (CD)  
spectrum [211,213]. These methods measure unstained or fixed samples in their native environment in 
real time. The signal from the CD spectrum reflects the protein conformation, particularly secondary 
protein structure. The principle is based on three hypotheses: (1) protein structure can be divided into 
homogeneous units with defined bond rotations parameters; (2) the contributions of different types of 
secondary structures are additive; (3) the contribution of bond rotations is limited to rotatory dispersion 
of the protein. A site-direct mutation caused by an nsSNP can alter both the secondary structural 
element and the bond rotations and can be evaluated by CD spectrum, by comparison with fully 
functional wild-type protein. 
Exon sequences typically have lower frequency of nsSNPs as compared with introns, because any 
changes of function in the resulting protein that lead to decreased fecundity or sterility are heavily 
selected against. However, a number of X-linked diseases are not caused by hereditary, but rather, 
spontaneous rare mutations in exon region, leading to disease [214]. These mutations can cause 
missense, nonsense or frame-shift mutations. In most cases, frame-shift mutations generate truncated 
proteins just like nonsense mutations. As mentioned, high frequency of partially translated proteins in 
patients usually indicates a functional depletion of the absent domain [197]. It is indeed a good starter 
to understand the pathology of a specific gene to a disease, however, additional information is needed to 
link a specific effect to a domain if more than one structural domain is deleted. 
For in vitro studies nsSNPs are selected based on several criteria. First, nsSNPs appearing in high 
frequencies in patients; second, an nsSNP site which is conserved and located in a homologous region;  
third, the resulting mutant is potentially important to the biochemical functions or structural fold. 
Generally, a nsSNP may not affect the structural the entire domain, instead, it is more likely to cause 
local structural changes. 
A CD spectrum can provide information of secondary structural changes. It is usually used in 
combination with temperature jump techniques for monitoring protein denaturation dynamics [201]. 
The intrinsic protein fluorescence measurement reflects conformational changes associated with aromatic 
amino acids, which is an effective tool for steady-state kinetics or binding kinetics analysis [215]. 
These profiles are represented by thermodynamic or chemical parameters to characterize protein 
stabilization and protein-substrate interactions. Data generated from these analyses also provide the 
basis for in silico modeling and dynamic simulation as described in Section 1. To evaluate the effects 
of nsSNPs in vitro, results from these analyses are determined by plotting the data or fitting the data 
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according to chemical and kinetic equations. For example, the Michaelis–Menten equation or the Hill 
equation is used to determine the equilibrium dissociation constant [216] and compare pathologic 
mutations with wild-type protein. A dysfunctional mutation in most cases leads to local structural 
instability [201] or decreased binding affinity [197], and in other cases some mutations result in 
increased binding affinity to substrate [217] or alternative substrate binding [218], which cause 
decreased enzyme turnover rate or competitive inhibition, respectively. 
Not all the nsSNPs alter the structural stability or binding affinity. For example, arginine finger is  
a conserved motif in helicases, and has postulated to play a role in adenosine triphosphate (ATP) 
hydrolysis and energy coupling. The defect in ATP hydrolysis activity can be measured either by 
chemical staining method or P32 radiation technique. Thus, most of mutations of conserved arginine 
affect ATP hydrolysis and some of them appear to be crucial for energy coupling, but none of them 
affect ATP and DNA-binding abilities [219]. Another exception is that the nsSNPs influence functional 
post-translational modification of wild-type protein by changing target sites or key flanking residues. 
For example, phosphorylation is one of the most common post-translational modifications, and turns 
many protein enzymes on and off. Phosphotryptic mapping is usually used to identify inducible 
phosphorylation sites that may regulate protein function by comparing phosphotryptic maps of protein 
phosphorylated in vitro by specific kinase with phosphotryptic maps obtained from original tissue. 
Once a kinase is identified, the wild-type protein, the wild-type protein treated with kinase and 
phosphorylation sites of mutant protein can be examined to reveal the role of post-translational 
regulation [220,221]. 
Overall, a protein-substrate binding assay or protein kinetics assay is also frequently used depending 
on the nature of the proteins. Various detection methods are available to visualize protein reactions,  
such as intrinsic protein fluorescence, immunolabeling, dye staining, and radiation. By obtaining 
enough evidence to understand the molecular pathogenesis, an in vitro functional rescue is supposed  
to be considered, since such disease caused by functional exon SNP is most likely to be targeted 
compared to SNP located in another region. Testing of potential pharmacological agents can lend 
insight into the malfunctioning protein and will determine if the protein can regain its wild-type 
activity in vitro leading to rescue of cell function [222]. 
4. In Vivo Analysis of Pathogenic Mutations 
4.1. Zebrafish as a Model for Studying the Downstream Effects of Non-Synonymous Single Nucleotide 
Polymorphism (nsSNPs) 
The canonical human disease model in fish is the zebrafish (Danio rerio). Practically all zebrafish 
genes have human equivalents with conserved molecular functions [223]. The many advantages of the 
zebrafish embryo and adult fish have been well documented [223–226]. SNPs have been employed in 
identifying the causative mutation of multiple diseases, through forward genetic screens, involving 
exposure of a male founder fish to a mutagenic compound, ENU (N-ethyl-N-nitrosourea), followed by 
screening for offspring with distinctive phenotypes; morphological, behavioral and molecular. Known 
SNPs that are found to associate with the phenotype using linkage studies have enabled positional 
mapping and genome wide association studies to identify the causative mutations [227]. Conversely, 
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reverse genetics has mostly involved knockdown or knockout of genes of interest, followed by studies 
of the mechanism and resulting phenotype. The next step in this evolution is to systematically 
mutagenize single nsSNPs within a gene, and study the molecular mechanism and resulting phenotype. 
The benefits of using zebrafish are several fold; multiple lines of fish can be created simultaneously, 
fish take up little room and are easy to house, there is a relatively short three month generation time for 
zebrafish—complemented by the number of embryos that can be produced by the founder fish—the 
large amounts of material available will expedite simultaneous morphological, behavioral, and 
molecular genetic analysis. 
The zebrafish provides a uniquely accessible organism with regard to genetic manipulation, as gene 
editing tools have sufficiently progressed to efficiently and reliably mutate single base pairs in vivo 
(discussed below). The heritably of such a mutagenesis strategy allows for the creation of lines of fish, 
each carrying a target nsSNP, which can be crossbred to fish carrying markers that will assist in 
analysis. However, this approach has some caveats. The goal is to mutagenize a single base pair  
in vivo, rather than produce a knockout or knockin of an entire gene. This means that the numerous 
conditional transgenic techniques that are available in zebrafish to spatially and temporally control 
expression [228], may not be relevant. 
Additionally, in case of X-linked genes, the effect is gender specific and it is not known how long 
males will survive. Moreover, the phenotype in heterozygous females is determined in part by  
X-inactivation, an apparently random process. It is likely that nsSNPs in zebrafish embryos may exhibit 
the same phenotypic outcomes. It remains to be determined if hemizygous females are sufficiently 
healthy to breed. Thus, one may have to resort to repeated mutagenesis for each batch of embryos, to 
produce sufficient material required for analysis. In this case, rather than breed mutagenized lines to 
zebrafish carrying reporter genes, one may need to perform the mutagenesis in embryos originating 
from several reporter gene lines. One of the great strengths of the zebrafish model is its adaptability in 
meeting new challenges. Developing a successful strategy for gene editing will allow to determine the 
downstream effects of nsSNPs, within the whole organism, individual tissues and down to the single 
cell level. 
4.2. Gene Editing to Introduce Individual nsSNPs within the Genome 
Several gene editing tools are now readily available; zinc-finger nucleases (ZFNs) [227], transcription 
activator-like effector nucleases (TALENs) [229–232] and the RNA guided CRISPR (clustered, 
regularly interspaced, short palindromic repeats)-Cas9 nuclease (CRISPR-associated enzyme)  
system [183,232,233]. These tools have become invaluable in manipulation of DNA in cell lines  
and in vivo, for example, in transiently transfected zebrafish embryos, or to establish heritable 
zebrafish lines. 
Recently, two research groups independently capitalized on the CRISPR-Cas9 system to perform 
genome scale knockouts of almost every gene in human cells [184,234]. Thus, a lentiviral expression 
vector with sgRNA (single-guide RNA), Cas9 and a puromycin selection marker, called lentiCRISPR [234] 
were developed. With 3–4 sgRNA’s per gene, a library with over 18,000 genes was developed, 
targeting 5' constitutive exons. It is, therefore, easy to appreciate why the CRISPR-Cas9 system has 
quickly become the method of choice, when such high throughput screens are possible. Moreover, the 
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system requires on just two components. Firstly, CRISPR normally functions as a type of acquired 
immune defense system that protects eubacteria and archaea cells from viruses, plasmids and  
phages [235,236]. CRISPR is an RNA molecule that acts as a guide RNA (gRNA), and when directly 
introduced into cells together with the second component, the Cas9 enzyme, which can induce double 
stranded cuts in DNA, effectively edits the DNA. Cas9 is a nuclease derived from a species of 
streptococcal bacteria and is recruited to the target DNA by the gRNA, where it cuts the DNA inside 
the gene of interest [237]. 
Several design elements should be incorporated into the system: the gRNA should be  
~80 nucleotides long, consisting of two regions: 20 nucleotides at the 5' end of the gRNA that are 
complementary to and bind the target DNA, the remaining nucleotides are designed to form a hairpin 
structure with variable length, depending on the plasmid selected to expresses the gRNA. The role of 
the hairpin is unclear, but may help to orient the gRNA for DNA binding and aid in forming a complex 
with Cas9. Additionally, the 5' end of the gRNA must bind to DNA with the sequence –NCC, i.e., any base 
pair, indicated by N, immediately adjacent to two cytosine residues. The gRNAs appear to bind  
most readily to DNA where the opposite strand contains a –NGG sequence, also known as PAM 
(protospacer adjacent motif). 
Multiple versions of Cas9 containing plasmids are available from the plasmid repository at Addgene 
(http://www.addgene.org/CRISPR) and several software programs are available to identify 20-base-pair 
regions in a DNA region of interest, including Massachusetts Institude of Tecnology’s CRISPR Design 
(http://www.crispr.mit.edu), the German Cancer Research Center E-CRISP (http://www.e-crisp.org/ 
E-CRISP/designcrispr.html) and the ZiFiT targeter (zifit.partners.org/ZiFiT). The first two also scan 
the whole genome to identify sequence regions of gRNA which might bind to similar, off-target sequences. 
Once the gRNA and Cas9 enzyme are expressed in cells, the complex does the rest and cuts both 
strands of the target DNA. The efficiency of gene editing needs to be tested, in addition to sequencing 
the DNA, to directly assess if the intended DNA was correctly targeted. Strategies for reducing off-target 
effects include transfecting the lowest amounts of Cas9 and gRNA expression plasmids that are 
necessary for on-target activity, or using a mutant version of Cas9, called Cas9 nickase, which cuts 
only the strand of DNA that binds the gRNA. Expressing Cas9 nickase in cells with a pair of gRNAs 
that bind different strands of the same DNA target results in double stranded nicks whose repair then 
leads to mutations. 
For certain applications ZFNs, which recognize longer stretches of target DNA and TALENs, 
which are fusions of a nuclease enzyme and DNA-binding domain protein, may provide alternative 
approaches [238,239]. If using the ZFN and TALEN systems, generally about a dozen different 
TALENs and many more ZFNs have to be tested, with DNA-binding domains that recognize different 
target sites, to find ones that work [240]. Moreover, the TALEN complex is less reliable at avoiding 
off-target sites. A much older method called site-directed mutagenesis, available as a PCR kit has 
several other considerations [241]. The PCR reaction does not maintain the original methylation of the 
DNA of interest, mixed template and reaction products have to be separated, the edited DNA requires 
the use of a retroviral vector for insertion into the genome and the insertion sites are difficult to 
control. Moreover, in very large genes the PCR method may be unsuitable due to the necessity for 
targeted primers, which work best at the 5' and 3' ends of the DNA. Manipulating sites outside of the  
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5' and 3' ends might mean having to perform PCR on a fragment of the DNA and then undertaking the 
extra step of DNA splicing in order to achieve the correct construct. 
5. Case Study: KDM5C and MECP2 Genes 
Since the first discovery of MECP2 [194] and KDM5C [242] as X-linked genes that contribute to 
Rett Syndrome and Mental Retardation, X-linked, Syndromic, Claes-Jensen type (MRXSCJ) [196,243,244], 
further disease-causing mutations have been identified [245,246]. However, the progress of functional 
studies on both gene products is quite different, because of different availability of corresponding 
protein. For KDM5C, only limited functional studies on domains from homologue genes are available, 
and most studies are still confined to genetics. On the other hand, even before the Zoghbi group found 
the mutations in MECP2 causing Rett syndrome [196], the ability to bind specifically to methylated 
DNA and the transcription repression capabilities of MECP2 were well understood [172,195,247,248], 
which provided a good basis for further investigating the effects of nsSNPs. Zoghbi’s group reported 
three missense mutations in the region encoding the highly conserved methyl-binding domain (MBD),  
and a frame-shift as well as a nonsense mutation that interrupts the transcription repression domain 
(TRD), by directly sequencing PCR product containing the coding exons and portions of the 3' UTR 
from patients. To date, IRSF, the MECP2 Gene Variation Database (http://mecp2.chw.edu.au/) has 
3271 mutations listed, which have been identified from Rett syndrome patients. The mutations are 
categorized into two main types, missense in the MBD and interrupted in the TRD shown in Figure 4A, 
with 43% being other mutations and 1% silent. The frequency for mutations encoded by the exon are 
shown in Figure 4B. Based on these data, biochemists are able to perform functional studies to reveal 
the effect of nsSNPs resulting in Rett syndrome. 
The first study on the functional consequences of human MECP2 mutations causing Rett syndrome 
was reported only one year after the SNP screening results [197]. Eight of the most frequent mutations 
found in patients are termed mutational “hotspots” (Figure 4B). Eleven mutations, including four missense 
mutations R106W, R133C, F155S, T158M and seven nonsense mutations L138X, R168X,  
E235X, R255X, R270X, V288X, R294X, were investigated for their effects on protein stability,  
methyl-CpG-binding and transcriptional repression capabilities [172,195,247,248]. Mutations found 
within the MBD abolished methylation specific binding to the DNA substrate and target genes lost the 
repression imposed by MeCP2 protein. The mutations causing the interruption of the TRD domain led 
to a failure to recruit the transcriptional repressors Sin3A and HDAC1 [249]. Further studies of the 
Rett syndrome mutants indicated that the MeCP2 protein can 1) bind tightly to biochemically defined  
12-mer nucleosome arrays [199]; (2) bind to four-way junction DNA in a structure-specific  
methyl-CpG-independent manner [200]; (3) compact chromatin via its three AT-hook domain [204]; 
and (4) bind specifically to 5-hydroxymethylytosine, enriched in the target gene promoter [202]. 
Biophysicists have performed structural studies using CD spectrum, inner fluorescence [201] and 
crystallography [144] and these data indicate that the Rett syndrome mutants have a unique role in 
DNA binding causing reduced thermal stability and an increased binding to methyl-CpG DNA. Through 
different methodologies used in these studies, one has a better understanding of the molecular 
mechanisms leading to Rett syndrome. However, the relationship between the nsSNPs in MeCP2 
protein and pathogenesis are still unknown. 
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Figure 4. (A) Percentage distribution of different Rett syndrome mutants. Three major types 
of sequence changes in specific domain are shown in the pie chart. Missense mutants in the 
Methyl-CpG-binding domain (MBD) and nonsense mutations that interrupt the transcription 
repression domain (TRD) are the major types. Synonymous mutations in exons and all 
mutants in the 5' UTR, the 3' UTR and introns are termed Silent; (B) The location and 
frequency of MECP2 Rett syndrome mutants. The most frequent 10 mutants are labeled. 
R106W, arginine to tryptophan point mutation at residue 106; R133C, arginine to cysteine 
point mutation at residue 133; T158M, threonine to methionine point mutation at residue 
158; R168X, arginine to stop codon at residue 168; R255X, arginine to stop codon at 
residue 255; R294X, arginine to stop codon at residue 294; R306C, arginine to cysteine 
point mutation at residue 306; R9fs, frame-shift from arginine at residue 9; frame-shift 
from lysine at residue 386. The first eight mutants are termed mutational “hotspots”. Data from 
the IRSF MECP2 Gene Variation Database. 
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A breakthrough was made by Greenberg’s group in 2003 [198], where they used an EMSA to show 
that the MeCP2 protein bound to the BDNF gene promoter III (later corrected to promoter IV) is a 
potent modulator in many aspects of neuronal development, and regulates the transcription of the 
BNDF gene. This process is further regulated by KCl induced membrane depolarization that triggers 
calcium-dependent phosphorylation of MeCP2 protein. Recent studies performed by Chromatin 
Immunoprecipitation followed by ChIP-Seq have identified even more downstream targets with altered 
gene expression in MECP2 mutant mice [250,251]. These results demonstrate that MECP2 has 
multiple roles in brain development and point the way for further pathogenesis studies [130]. 
Recently, four new activity-dependent phosphorylation sites (S86, S274, T308 and S421) were 
revealed, that might regulate the MECP2 function using phosphotryptic-mapping techniques [221]. 
This study identified phosphorylation of T308 as an activity sensor that controls the interaction of 
MeCP2 protein with nuclear receptor co-repressor (NCoR/SMRT) complex. At the same time, it was 
also found that the mutational hotspot R306C, proximal to the T308 phosphorylation site, abolishes the 
binding to the NCoR complex [203]. These two studies implied that the two mutations have similar 
contributions to the neurological deficits in Rett Syndrome. Methods used in MECP2 studies along 
with the historic timeline of research milestone are listed below (Table 2). 
Using the above methodology, an in silico analysis of the nsSNP of interest was performed as a 
proof of principle. Several web servers were utilized to predict in silico the stability changes upon 
mutations; D87G, and D402Y in the KDM5C protein, and the mutations; D97Y, L100R, R106W, 
R111G, Y120P, Q128P, E137G, P152R and F155S in the MeCP2 protein (Table 3). The structure of 
human KDM5C, which is a large protein with 1560 residues, is not available, thus, the structure was 
built through homology modeling using JACKAL [252,253]. First, sequence alignments were done 
using Psi Basic Local Alignment Search Tool (PSI-BLAST) in National Center for Biotechnology 
Information (NCBI) to identify conserved regions and identical structures. The D87G mutation in 
KDM5C is in an AT-rich interaction domain (ARID) and the sequence of this domain and the protein 
with PDB ID 2JRZ were found to have a 98% identity with no gaps in sequences. Therefore, this 
structure was used as a template in homology modeling. The region containing the D402Y mutation 
was modeled using two different structures. One of them is the protein with PDB ID 3DXT, which is 
38% identical with 11% gaps, and the other one is the protein with PDB ID 4IGO, which is 54% 
identical with 6% gaps. Since there are no experimental results to compare to, both of these structures 
were independently utilized as a measure of consistency in results. 
Table 3. Webservers used in the case study along with short description of their functionality. 
Webservers Input Method Summary 
MuStab Sequence Support vector machine (SVM), trained on various amino acid features 
dFIRE/DFIRE2 Structure Statistical potentials with orientation-dependent interactions 
FoldX Structure Potential with weighted sum of empirical contributions to free energy 
Eris Structure 
Molecular mechanics type potential with weighted sum of 
contributions to free energy 
Two structures were used for MeCP2 protein modeling, Protein Data Bank (PBD) ID 1QK9  
(the human MECP2 structure) and PBD ID 3C2I, which has 94% identity with no gaps in the 
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sequence. After building the structures using JACKAL, the termini were patched and hydrogen atoms 
were added using Visual Molecular Dynamics (VMD) [254]. The wild-type structures were (1) relaxed 
for 500 steps with backbone atoms restrained with 5 kcal/mol-Å force constant; (2) the proteins were 
energy minimized for another 35,000 steps with no restrains ensuring full convergence; (3) the mutant 
proteins were built using these structures in JACKAL; and (4) the mutants were minimized for  
500 steps using Nanoscale Moleclar Dynamics (NAMD) [255,256]. 
After that, the MuStab [21,22] server was utilized, which uses a sequence-feature based prediction 
with support vector machines. The parts of the sequences used to prepare the wild-type structures were 
fed into the server together with the pH and temperature information from experimental structures.  
The server identified the mutants as stabilizing or destabilizing with corresponding confidence values 
of the predictions. Then, the wild-type and mutant structures described above were used in the  
(dipolar DFIRE (dDFIRE) and DFIRE2 [35,36] server, which uses a structure-based statistical 
potential, and subsequently the dDFIRE and DFIRE2 energies were obtained for each structure. The 
stability changes upon mutations were calculated by subtracting the wild-type energies from mutant 
energies. Finally, the Eris [124] and FoldX [33,34] servers were utilized, which make structure-based 
predictions of stability changes upon mutation based on first-principles. The same wild-type structures 
were used in these servers and the servers perform the mutations and use their mutant structures to 
calculate the ∆∆G upon the mutations. In summary, except for the MuStab servers, the other three 
servers produced positive or negative ∆∆G values indicating destabilizing or stabilizing mutations. 
In summary, all four servers produced consistent results in general for nine mutants out of 11 as 
summarized in Table 4. The consistency of the results was assured in three aspects. First, the results 
were collected from several servers, which utilize different methodologies; Second, different structures 
were used for the same regions of the proteins where applicable and the results from those were 
collected independently and compared; Third, the Eris and FoldX results were collected from a reverse 
path. For example for the D87G mutant of KDM5C protein, the mutant structure was utilized and the 
servers were used to mutate it back to the wild-type to determine whether an opposite effect was 
obtained or not. An opposite effect was seen for this mutant from both Eris and FoldX. This was 
specifically done to improve the initially inconsistent results of the two MECP2 mutants (D97Y and 
L100R) shown in Table 2. In summary, two KDM5C mutations, D87G and D402Y, were successfully 
identified as destabilizing and stabilizing, respectively. Also, eight MECP2 mutants, namely L100R, 
R106W, R111G, Y120P, Q128P, E137G, P152R and F155S were successfully identified as destabilizing. 
However, in-depth studies are being performed to assess the accuracy of different web servers. 
MECP2 and KDM5C have multiple roles in embryonic development and proper organism function. 
GO annotation indicates that MECP2 is involved in 42 biological processes (UniProtKB/Swiss-Prot: 
P51608), whereas five have been identified for KDM5C (UniProtKB/Swiss-Prot: P41229). This is an 
indication that the role of KDM5C is more restricted than for MECP2. Large numbers of zebrafish 
embryos can simultaneously undergo gene editing and then they can be non-invasively screened for 
morphology and behavior during early development. Analyzing the gross morphology and behavioral 
phenotype of mutagenized embryos goes hand in hand and changes in behavior are likely reflected in 
morphological abnormalities. In addition to standard gross morphological observations, hundreds of strains 
of zebrafish are now available with fluorescent markers driven by promoters for practically every cell type, 
allowing for direct, real time analysis of fluorescence in living embryos (http://www.zfin.org) [257]. 
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Performing gene editing in transgenic reporter lines selected for neuronal and other cell types, can be 
scaled as needed. 
Table 4. Stability changes upon mutations. Stabilizing mutations are highlighted in blue, 
and the rest are identified as destabilizing. 
MECP2  
Mutants 
∆∆G (kcal/mol) Effect, Confidence 
dDFIRE  
(1qk9) 
DFIRE2  
(1qk9) 
dDFIRE 
(3c2i) 
DFIRE 
(3c2i) 
Eris  
(1qk9) 
Eris 
(3c2i) 
FoldX 
(1qk9) 
FoldX  
(3c2i) 
MuStab 
D97Y −1.76 −2.36 −0.73 −1.36 >10 −2.08 5.28 1.28 Stabilizing, 26% 
L100R 5.95 3.89 3.66 2.10 2.68 3.93 2.3 2.13 Destabilizing, 90% 
R106W −1.47 −2.24 −0.63 −2.13 >10 9.71 10.9 4.12 Stabilizing, 27% 
R111G 1.73 1.01 2.15 1.51 3.22 8.57 1.56 1.71 Destabilizing, 94% 
Y120P 2.69 2.30 3.66 2.45 −8.67 7.48 0.53 1.95 Destabilizing, 90% 
Q128P 1.59 0.52 0.65 0.57 >10 8 1.34 0.12 Destabilizing, 92% 
E137G 2.68 1.19 3.13 1.63 3.86 5.41 2.22 2.29 Destabilizing, 88% 
P152R 7.54 3.74 2.05 1.13 >10 0.44 2.28 1.95 Destabilizing, 81% 
F155S 5.16 4.38 6.62 5.17 6.8 5.04 5.73 4.03 Destabilizing, 93% 
KDM5C  
Mutant 
dDFIRE (2jrz) DFIRE2 (2jrz) Eris (2jrz) FoldX (2jrz) MuStab 
D87G 0.34 0.994 4.48 0.53 Destabilizing, 94% 
KDM5C  
Mutant 
dDFIRE  
(3dxt) 
DFIRE2  
(3dxt) 
dDFIRE 
(4igo) 
DFIRE2 
(4igo) 
Eris  
(3dxt) 
Eris 
(4igo) 
FoldX 
(3dxt) 
FoldX  
(4igo) 
MuStab 
D402Y −0.27 −1.379 0.19 −0.741 −4.14 −1.49 −1.64 −0.6 Stabilizing, 27% 
As one study indicated that a point mutant of MECP2 affects swimming behavior in zebrafish [258], 
assessing the highly stereotyped motor behaviors of developing embryos is targeted [259]. Within the 
first 24 h, embryos coil rhythmically within the chorion, as slow-muscle begins to function—this behavior 
can be captured using video surveillance of embryos for rapid review. Following escape, or removal 
from the chorion at two days post fertilization (2 dpf), embryos will display an escape response to light 
tactile stimulation. Thereafter, by 3 dpf the fish can swim using voluntary muscles. Velocity and turn 
frequency are two measurements that can be assessed using Noldus DanioVision or ViewPoint 
Zebrafish, two software programs commercially available. Indeed, there is a plethora of imaging 
strategies, including high throughput automated systems driven by numerous available software 
applications that can be employed to analyze behavioral phenotypes [259]. 
As MECP2, for example, results in several separate phenotypes we expect that these analyses will 
identify characteristic spatial and temporal differences for each phenotype. Additionally, by using 
video tracking of development and fluorescent reporter lines, subtle differences for individual nsSNPs 
within a phenotype can be identified. Rett syndrome has at least three subtypes, but the spatial and 
temporal molecular mechanisms are virtually unknown. The subtle, or possibly not so subtle, differences 
in downstream effects leading to the clinically observed phenotypes are essentially a mystery. The data 
from these preliminary, non-invasive observations can provide insight into the mechanism and 
progression of disease phenotypes caused by individual nsSNPs. Additionally, critical developmental 
Int. J. Mol. Sci. 2014, 15 9699 
 
time points, such as the onset of fluorescent reporter gene changes can be identified and inform 
molecular genetic analysis that can be performed simultaneously. 
One of the major objectives in the field is to understand the disease mechanism. To achieve this, the 
spatial and temporal gene expression changes, which are expected in embryos when pathogenic 
nsSNPs are present, need characterizing. Indeed, even the normal downstream interactions of MECP2 
and KDM5C are not yet fully established. Molecular genetic analysis can include genomics, 
transcriptomics (gene expression arrays), and proteomics. The purpose is to determine the omic 
signature for every nsSNP within a region of interest, whole gene, or through high throughput 
methods, the whole genome. Using genomics the core and differential-omic signatures of each nsSNP 
within genes such as MECP2 and KDM5C can be determined. As already discussed, several diseases 
arise from multiple nsSNPs within the multiple binding domain (MBD) of MeCP2 protein. The MBD 
encompasses a 222 bp/74 amino acid region and within this a DNA binding domain a 90 bp/30 amino acid 
region is identified. A key question is if there is a core -omic signature that can be identified linking 
multiple nsSNPs to a single disease state and if there are distinct differential signatures between groups 
of nsSNPs. 
Evaluating the transcriptome of mutagenized embryos utilizing NGS is an important step in 
understanding the molecular basis for each phenotype. To facilitate a comprehensive or more focused 
analysis, such as in neuronal tissue in X-linked mental retardations, analysis of the transcriptome at 
critical developmental stages, identified during morphological and behavioral analysis, can be 
performed using a variety of samples, including whole embryos, selected tissues, multiple pooled 
embryos, single specimens and single cells. The objective of this approach is to establish the core 
genetic markers, both unregulated and downregulated genes, for each nsSNP. Depending on the 
desired information the analysis can focus on the earliest effects of a nsSNP prior to the overt 
appearance of the disease, the core changes in gene information at the point of onset of morphological 
anomalies, the appearance of behavioral symptoms, or even when the disease is established and 
clinical symptoms are present. These data can facilitate comparative genomics between each mutation, 
for example, the two KDM5C mutations, D87G and D402Y, one destabilizing and the latter 
stabilizing. In MECP2 mutants, nsSNPs that are all destabilizing, are namely L100R, R106W, R111G, 
Y120P, Q128P, E137G, P152R and F155S. In the case of both MECP2 and KDM5C genes, which 
both display polyphenotypic outcomes, identifying the core and differential genetic changes for and 
between each nsSNP tested can facilitate development of a genetic fingerprint database. 
Using the transcriptome screening method, all pathogenic nsSNPs in a gene can be evaluated, 
lending insight into the molecular mechanism governing each phenotype. Comparative genomics will 
confirm: (1) the nsSNPs within a single gene that display equivalent transcriptomes; (2) separate out 
nsSNPs with differential RNA signatures, even though they are classified as causing the same disease; 
and thus (3) establish grouping of nsSNPs based on their molecular signature, which will lend itself to 
analysis of the underlying mechanism. Based on clinical studies, it can be predicted that all nsSNPs 
causing Rett syndrome, for instance, will share a core RNA signature, and that the pleiotropic effect of 
nsSNPs within a single gene, will have a transcriptome correlated to the disease outcome. It is 
tempting to speculate that all nsSNPs in the DNA binding domain of MECP2 would result in Rett 
syndrome. Clinical data, however, refute this notion, with individual DNA binding domain nsSNPs not 
only causing phenotypic variations within Rett syndrome itself, but also entirely different disease 
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phenotypes such as Encephalopathy (neonatal severe). As an illustration, this methodology has the 
potential to reveal the causative differences between the transcriptome of three Rett syndrome 
subtypes, including classical Rett syndrome [196], Rett syndrome with preserved speech variant [260] 
and Rett syndrome with the Zappella variant [261,262], and also identify the causative differences 
between each of the several disease specific phenotypes. 
To accelerate analysis, and develop a readout for potential therapeutics, establishing an RNA 
signature for each nsSNP or group of SNPs, if they prove to have a collective RNA signature, is 
needed. Using a digital, molecular barcoding chemistry (Nanostring Technologies, Seattle, WA, USA), 
up to 800 genes can be profiled simultaneously. Over and above that, it is now possible to develop 
nCounter Elements assays in lab. Moreover, the readout is quantitative, indicating transcript number 
for each gene tested. Once a set of unique RNA signatures is established for groups of nsSNPs 
exhibiting the same phenotype, it will no longer be necessary to perform whole genome transcriptomics, 
rather, nCounter assays can synchronously analyze multiple samples, providing a direct readout of each 
signature. Given the speed, reproducibility and sheer number of genes/set of signature that can be analyzed 
simultaneously it seems likely that this technology is set to overtake Reverse Transcription-PCR  
(RT-PCR) as a screening method.  
The use of an RNA signature can be expanded as a comparative tool between species, in testing the 
effects of morpholino knockdowns, for example, or comparing zebrafish lines carrying various genetic 
manipulations. A few mutant lines are currently available from Zfin. MECP2, (RefSeq: XM_005166687) 
has a mutant line available, mecp2fh232/fh232(AB) and KDM5C (RefSeq: NM_001123234), has four 
known mutants; la026535Tg, la026536Tg, sa15146 and sa17413. These can be used as proof of 
principle for the RNA signatures. Indeed this need not to be limited to zebrafish, but can be extended 
to mouse lines and even human samples, either lab generated or patient samples.  
To further evaluate the effect of key candidate downstream effectors whole mount zebrafish are amenable 
to high throughput, high resolution in situ hybridization screening using robotic processors [263,264]. 
This data is essential to provide a tissue and cell level analysis when investigating disease mechanisms. 
Finally, zebrafish reporter lines can be established, based on the above analyses, with fluorescent 
marker gene expression, driven by the regulatory element of sentinel markers. This will provide 
transgenic zebrafish embryos to screen bioactive small molecule, biologics and other potential 
therapeutic interventions. 
6. Conclusions 
In the age of rapid advances of genome sequencing techniques, the development of methods  
for predicting disease-causing missense mutations or nsSNPs has gained increased significance.  
The straightforward approach is to build a library of DNA defects associated with particular diseases, 
i.e., database of genotypes causing a particular disease. The increasing number and size of such 
databases is essential for fast and precise diagnostics, since the only information required is the 
individual’s genome. Once the individual genome is mapped onto the database of the diseases’ 
genotypes, the prediction of the disease predisposal can be done instantly. However, recent completion 
of the 1000 genomes pilot project [265] revealed that most individuals carry 250–300 loss-of-function 
variants in annotated genes and 50–100 variants previously implicated in inherited disorders [266].  
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In addition to this observation, it is known that the severity of a disease depends on many factors,  
and, for individuals carrying the same disease-causing mutation(s), the manifestation can be quite different. 
These observations indicate the necessity of further development of approaches to predict the 
disease-causing effect without the help of databases and comparison. As outlined in this review, the 
best approach, perhaps, is to rely on collective efforts that utilize wider perspectives from both 
computational and experimental approaches. It is unlikely that in vitro and in vivo approaches will be 
applicable for investigating each gene variation, so in silico methods can be applied first to deliver 
testable hypotheses and to reduce the number of candidate genes/variations to a number appropriate for 
experimental testing. In vitro experiments provide a direct measure of the effect of mutation(s) on the 
biochemical reactions associated with a particular gene and can also be very insightful in revealing the 
effect of mutation(s) on various biophysical characteristics as stability and interactions. Also, results 
from those experiments such as thermostability play a key role in the development and validation of  
in silico methods. However, such experiments are time and labor intensive and require careful 
selection of target genes and mutations. At the same time, the in vitro experiments are the ultimate 
proof of the biophysical effects caused by the mutations. With that being said, however, to understand 
the overall effect of a gene variant requires in vivo studies, which are more directly relevant to human 
disease than in vitro studies. For example, the neuropathology (phenotype, behavior, brain morphology 
and function) of variants involved in X-linked mental retardation can only be discerned in a whole 
organism. For initial studies, zebrafish are highly suited to this task as they are genetically tractable, 
available in large numbers, develop quickly and external to the mother. Importantly, they have similar 
organ systems to mammals, share significant genetic sequence identity to humans and in many cases, 
within five days of the onset of development, begin to manifest disease phenotypes. These phenotypic 
and genetic similarities to humans make zebrafish superior to flies, worms and yeast screens. The large 
number of fluorescent reporter lines available, driven by cell specific enhancers in this optically clear 
organism allow for live imaging directly in the whole organism. This provides a real-time readout of 
affected cells, tissue and organs, which is not possible in mammalian models. The zebrafish is  
thus extremely useful and cost efficient when screening large numbers of variants for behavioral, 
morphological, physiological and molecular pathway analysis, including downstream genetic and 
epigenetic outcomes [267,268]. Further studies can then be transferred to mice and other mammalian 
models as appropriate. These studies are lengthy, time consuming and expensive, but vital in the next 
stage of disease modeling. By narrowing down variants of interest highly focused mammalian studies 
are more efficient and productive. In combination, in silico, in vitro and in vivo methods all have 
particular roles in identifying and understanding the mechanism of disease variants. 
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